These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 16257373)

  • 1. Keynote review: phosphodiesterase-4 as a therapeutic target.
    Houslay MD; Schafer P; Zhang KY
    Drug Discov Today; 2005 Nov; 10(22):1503-19. PubMed ID: 16257373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of 1-benzylxanthines on cyclic AMP phosphodiesterase 4 isoenzyme.
    Suzuki H; Sawanishi H; Nomura M; Shimada T; Miyamoto K
    Biol Pharm Bull; 2006 Jan; 29(1):131-4. PubMed ID: 16394525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase-4 as a potential drug target.
    Zhang KY; Ibrahim PN; Gillette S; Bollag G
    Expert Opin Ther Targets; 2005 Dec; 9(6):1283-305. PubMed ID: 16300476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization.
    Houslay MD; Adams DR
    Biochem J; 2003 Feb; 370(Pt 1):1-18. PubMed ID: 12444918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term regulation of PDE4 activity.
    Manganiello V
    Br J Pharmacol; 2002 Jun; 136(3):339-40. PubMed ID: 12023934
    [No Abstract]   [Full Text] [Related]  

  • 7. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling.
    Conti M; Richter W; Mehats C; Livera G; Park JY; Jin C
    J Biol Chem; 2003 Feb; 278(8):5493-6. PubMed ID: 12493749
    [No Abstract]   [Full Text] [Related]  

  • 8. cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling.
    Houslay MD; Baillie GS; Maurice DH
    Circ Res; 2007 Apr; 100(7):950-66. PubMed ID: 17431197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression, intracellular distribution and basis for lack of catalytic activity of the PDE4A7 isoform encoded by the human PDE4A cAMP-specific phosphodiesterase gene.
    Johnston LA; Erdogan S; Cheung YF; Sullivan M; Barber R; Lynch MJ; Baillie GS; Van Heeke G; Adams DR; Huston E; Houslay MD
    Biochem J; 2004 Jun; 380(Pt 2):371-84. PubMed ID: 15025561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding.
    Huai Q; Wang H; Zhang W; Colman RW; Robinson H; Ke H
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9624-9. PubMed ID: 15210993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioural effects of selective PDE4 inhibitors in relation to inhibition of catalytic activity and competition for [3H]rolipram binding.
    Kapui Z; Bence J; Boronkay E; Mikus E; Urbán Szabó K; Baranyi A; Arányi P
    Neurobiology (Bp); 1999; 7(1):71-3. PubMed ID: 10746252
    [No Abstract]   [Full Text] [Related]  

  • 12. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors.
    Kelly JJ; Barnes PJ; Giembycz MA
    Br J Pharmacol; 1998 May; 124(1):129-40. PubMed ID: 9630352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors.
    Saldou N; Obernolte R; Huber A; Baecker PA; Wilhelm R; Alvarez R; Li B; Xia L; Callan O; Su C; Jarnagin K; Shelton ER
    Cell Signal; 1998 Jun; 10(6):427-40. PubMed ID: 9720765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
    Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY
    Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4.
    Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D
    Cell Signal; 2001 Apr; 13(4):287-97. PubMed ID: 11306246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors.
    Castro A; Jerez MJ; Gil C; Martinez A
    Med Res Rev; 2005 Mar; 25(2):229-44. PubMed ID: 15514991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase 4 regulation of cyclic AMP in pulmonary remodelling: potential roles for isoform selective inhibitors.
    Shepherd MC
    Pulm Pharmacol Ther; 2006; 19(1):24-31. PubMed ID: 16046159
    [No Abstract]   [Full Text] [Related]  

  • 18. New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease.
    Barnette MS; Underwood DC
    Curr Opin Pulm Med; 2000 Mar; 6(2):164-9. PubMed ID: 10741778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity.
    Xu RX; Hassell AM; Vanderwall D; Lambert MH; Holmes WD; Luther MA; Rocque WJ; Milburn MV; Zhao Y; Ke H; Nolte RT
    Science; 2000 Jun; 288(5472):1822-5. PubMed ID: 10846163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cAMP-specific phosphodiesterase PDE4D3 is regulated by phosphatidic acid binding. Consequences for cAMP signaling pathway and characterization of a phosphatidic acid binding site.
    Grange M; Sette C; Cuomo M; Conti M; Lagarde M; Prigent AF; Némoz G
    J Biol Chem; 2000 Oct; 275(43):33379-87. PubMed ID: 10938092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.